2019年《糖尿病患者骨折风险管理中国专家共识》解读

摘要/Abstract

中图分类号:

R587.1

赵红燕, 刘建民. 2019年《糖尿病患者骨折风险管理中国专家共识》解读[J]. 诊断学理论与实践, 2020, 19(03): 225-228.

参考文献31

[1]	Xu Y, Wang LM, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9):948-959. doi:10.1001/jama.2013.168118 URL
[2]	Bragg F, Holmes MV, Iona A, et al. Association between diabetes and cause-specific mortality in rural and urban areas of China[J]. JAMA, 2017, 317(3):280-289. doi:10.1001/jama.2016.19720 URL
[3]	Miyake H, Kanazawa I, Sugimoto T. Association of bone mineral density, bone turnover markers, and vertebral fractures with all-cause mortality in type 2 diabetes mellitus[J]. Calcif Tissue Int, 2018, 102(1):1-13.
[4]	Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study[J]. J Clin Endocrinol Metab, 2006, 91(9):3404-3410. doi:10.1210/jc.2006-0614 URL
[5]	Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health[J]. Endocr Rev, 2015, 36(2):194-213. doi:10.1210/er.2012-1042 URL
[6]	Guo Y, Wang YF, Cheng F, et al. Assessment of risk factors for fractures in patients with type 2 diabetes over 60 years old: a cross-sectional study from northeast China[J]. J Diabetes Res, 2020, 2020:1508258.
[7]	Stumpf U, Hadji P, van den Boom L, et al. Incidence of fractures in patients with type 1 diabetes mellitus-a retrospective study with 4420 patients[J]. Osteoporos Int, 2020, 31(7):1315-1322.
[8]	Kaur H, Joshee P, Franquemont S, et al. Bone mineral content and bone density is lower in adolescents with type 1 diabetes: A brief report from the RESISTANT and EMERALD studies[J]. J Diabetes Complications, 2018, 32(10):931-933. doi:10.1016/j.jdiacomp.2018.06.004 URL
[9]	Shah VN, Harrall KK, Shah CS, et al. Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature[J]. Osteoporos Int, 2017, 28(9):2601-2610. doi:10.1007/s00198-017-4097-xpmid:28580510
[10]	Thong EP, Herath M, Weber DR, et al. Fracture risk in young and middle-aged adults with type 1 diabetes mellitus: A systematic review and meta-analysis[J]. Clin Endocrinol (Oxf), 2018, 89(3):314-323. doi:10.1111/cen.13761 URL
[11]	Janghorbani M, van Dam RM, Willett WC, et al. Syste-matic review of type 1 and type 2 diabetes mellitus and risk of fracture[J]. Am J Epidemiol, 2007, 166(5):495-505. pmid:17575306
[12]	Nicodemus KK, Folsom AR, Iowa Women's Health S. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women[J]. Diabetes Care, 2001, 24(7):1192-1197. pmid:11423501
[13]	Jiajue RZ, Qi X, Jiang Y, et al. Incident fracture risk in type 2 diabetic postmenopausal women in mainland China: Peking Vertebral Fracture Study[J]. Calcif Tissue Int, 2019, 105(5):466-475. doi:10.1007/s00223-019-00598-x URL
[14]	Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes[J]. JAMA, 2011, 305(21):2184-2192. doi:10.1001/jama.2011.715pmid:21632482
[15]	Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications[J]. J Bone Miner Res, 2009, 24(4):702-709. doi:10.1359/jbmr.081207 URL
[16]	Jiang N, Xia W. Assessment of bone quality in patients with diabetes mellitus[J]. Osteoporos Int, 2018, 29(8):1721-1736. doi:10.1007/s00198-018-4532-7pmid:29736760
[17]	中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5):413-443.
[18]	Ho-Pham LT, Nguyen TV. Association between trabecular bone score and type 2 diabetes: a quantitative update of evidence[J]. Osteoporos Int, 2019, 30(10):2079-2085. doi:10.1007/s00198-019-05053-zpmid:31214749
[19]	Chen FP, Kuo SF, Lin YC, et al. Status of bone strength and factors associated with vertebral fracture in postmenopausal women with type 2 diabetes[J]. Menopause, 2019, 26(2):182-188.
[20]	Carvalho AL, Massaro B, Silva L, et al. Emerging aspects of the body composition, bone marrow adipose tissue and skeletal phenotypes in type 1 diabetes mellitus[J]. J Clin Densitom, 2019, 22(3):420-428. doi:S1094-6950(18)30072-6pmid:30100221
[21]	Burghardt AJ, Issever AS, Schwartz AV, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2010, 95(11):5045-5055. doi:10.1210/jc.2010-0226pmid:20719835
[22]	Samelson EJ, Demissie S, Cupples LA, et al. Diabetes and deficits in cortical bone density, microarchitecture, and bone size: Framingham HR-pQCT Study[J]. J Bone Miner Res, 2018, 33(1):54-62. doi:10.1002/jbmr.3240 URL
[23]	Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes[J]. J Bone Miner Res, 2012, 27(2):301-308. doi:10.1002/jbmr.556pmid:22052532
[24]	Iki M, Fujita Y, Tamaki J, et al. Trabecular bone score may improve FRAX(R) prediction accuracy for major osteoporotic fractures in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men(FORMEN) Cohort Study[J]. Osteoporos Int, 2015, 26(6):1841-1848. doi:10.1007/s00198-015-3092-3pmid:25752623
[25]	Leslie WD, Johansson H, McCloskey EV, et al. Comparison of methods for improving fracture risk assessment in diabetes: The Manitoba BMD Registry[J]. J Bone Miner Res, 2018, 33(11):1923-1930. doi:10.1002/jbmr.3538 URL
[26]	Habib ZA, Havstad SL, Wells K, et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2010, 95(2):592-600. doi:10.1210/jc.2009-1385 URL
[27]	Lin HF, Liao KF, Chang CM, et al. Use of thiazolidinediones and risk of hip fracture in old people in a case-control study in Taiwan[J]. Medicine (Baltimore), 2017, 96(36):e7712. doi:10.1097/MD.0000000000007712 URL
[28]	Erythropoulou-Kaltsidou A, Polychronopoulos G, Tziomalos K. Sodium-glucose co-transporter 2 inhibitors and fracture risk[J]. Diabetes Ther, 2020, 11(1):7-14. doi:10.1007/s13300-019-00724-wpmid:31734830
[29]	Ben-Porat T, Elazary R, Sherf-Dagan S, et al. Bone health following bariatric surgery: implications for mana-gement strategies to attenuate bone loss[J]. Adv Nutr, 2018, 9(2):114-127. doi:10.1093/advances/nmx024pmid:29659692
[30]	Lu CW, Chang YK, Chang HH, et al. Fracture risk after bariatric surgery: A 12-year nationwide cohort study[J]. Medicine (Baltimore), 2015, 94(48):e2087.
[31]	Ferrari SL, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge[J]. Osteoporos Int, 2018, 29(12):2585-2596. doi:10.1007/s00198-018-4650-2pmid:30066131

2019年《糖尿病患者骨折风险管理中国专家共识》解读

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献31

相关文章15

编辑推荐

Metrics

本文评价

[1]	中华医学会内分泌学分会.新型冠状病毒肺炎疫情下骨质疏松症管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 133-135.
[2]	中华医学会内分泌学分会.新型冠状病毒肺炎疫情下糖尿病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 136-138.
[3]	陈煦阳, 顾卫琼.胰岛素自身抗体临床检测应用局限及对策研究进展[J]. 诊断学理论与实践, 2022, 21(01): 95-98.
[4]	王广宇, 杨昕, 张立娟, 谭姣容.住院新诊断2型糖尿病男性患者血浆总睾酮水平与骨钙素的相关性研究[J]. 诊断学理论与实践, 2021, 20(06): 573-578.
[5]	章淼滢, 罗飞宏.儿童单基因糖尿病诊治进展及诊断策略[J]. 诊断学理论与实践, 2021, 20(03): 229-232.
[6]	范秋灵.糖尿病肾病和非糖尿病慢性肾脏病患者应用钠-葡萄糖协同转运蛋白2抑制剂：预后评估及相关指南解读[J]. 诊断学理论与实践, 2021, 20(02): 130-137.
[7]	邓琳, 丁怡, 汪萍, 卞炳贤, 沈立松.尿中性粒细胞明胶酶相关脂质运载蛋白/肌酐比值在2型糖尿病肾损伤的早期诊断及病情评估中的临床应用[J]. 诊断学理论与实践, 2019, 18(1): 61-65.
[8]	姚小艳, 陈君.上海地区孕妇维生素D水平调查及其与妊娠期糖尿病发生的相关性研究及其预测价值探索[J]. 诊断学理论与实践, 2019, 18(06): 634-639.
[9]	顾勤, 王泰蓉, 陈荔萍, 吴舒窈, 沈祎.社区老年女性糖尿病患者尿路感染常见病原菌调查[J]. 诊断学理论与实践, 2019, 18(05): 538-542.
[10]	刘珊珊, 牛静雅, 王天歌, 李勉, 赵志云, 徐瑜, 陆洁莉, 徐敏, 毕宇芳, 张迪.上海淞南社区2型糖尿病患者合并其他心血管代谢异常的现况流行病学调查[J]. 诊断学理论与实践, 2019, 18(03): 323-328.
[11]	张祎昀, 徐雷, 唐兆生, 陈英华, 窦琴, 冯波.2型糖尿病合并戊型肝炎患者的临床特征分析[J]. 诊断学理论与实践, 2018, 17(05): 557-561.
[12]	周鑫昀, 沈立松, 潘秀军.新型自身抗体及相关抗原在1型糖尿病诊治中的研究进展[J]. 诊断学理论与实践, 2018, 17(03): 352-356.
[13]	季鹏程, 张舒, 孙璟, 江石湖.上海地区部分中老年糖尿病患者体内维生素水平分析[J]. 诊断学理论与实践, 2018, 17(03): 285-289.
[14]	胡如英.我国糖尿病的流行特点及社区管理和干预策略[J]. 诊断学理论与实践, 2018, 17(03): 357-359.
[15]	谭姣容, 田冬梅, 杨昕, 张立娟, 王芳, 苏玉霞.维生素D缺乏与糖尿病患者糖尿病肾病发生率的关系研究：前瞻性3年随访研究[J]. 诊断学理论与实践, 2018, 17(02): 176-180.